September MIMS update

Some recent changes to medicines listings, including new products, indications and contraindications  New Products Remibrutinib (Rhapsido) is an oral Bruton’s tyrosine kinase (BTK) inhibitor. BTK is an intracellular protein selectively expressed in mast cells, basophils, B cells, macrophages and thrombocytes. BTK is a key node of the intracellular signalling via Fc epsilon receptor-1 (FcεRI), Fc